Abstract
Background
Cytomegalovirus (CMV) is the most common opportunistic infection after solid-organ transplantation, increasing morbidity and mortality. Three months of oral valganciclovir have been shown to provide effective prophylaxis. Late-onset CMV disease, occurring after the discontinuation of prophylaxis, is now increasingly recognised.
Aims
To investigate the incidence and the time of detection of CMV infections in liver transplant recipients who received CMV prophylaxis.
Methods
Retrospective review of 64 high- and moderate-risk patients with 1 year of follow-up.
Results
The incidence of CMV infection was 12.5%, with 4.7% disease. All cases of symptomatic CMV disease were of late-onset.
Conclusions
The incidence of CMV infections in this study was low compared with literature reports; however, the late-onset disease is an emerging problem. Detection of late-onset disease may be delayed because of less frequent clinic follow-up visits. Increased regular laboratory monitoring may allow earlier detection at the asymptomatic infection stage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Razonable RR, Emery VC (2004) Management of CMV infection and disease in transplant patients (Consensus article: International Herpes Management Forum management recommendations). Herpes 11:77–86
Patel R, Paya CV (1997) Infections in solid-organ transplant recipients. Clin Microbiol Rev 10:86–124
Hodson EM, Barclay PG, Craig JC, et al (2005) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (Cochrane review). Cochrane Database Syst Rev 4:CD003774
Snydman DR (1999) Infection in solid organ transplantation. Transpl Infect Dis 1:21–28. doi:10.1034/j.1399-3062.1999.10103.x
Baillie GM (2006) Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy. Am J Health Syst Pharm 63(Suppl 5):10–16. doi:10.2146/ajhp060378
(2004) Cytomegalovirus. Am J Transplant 4(Suppl 10):51–58
Preiksaitis JK, Brennan DC, Fishman J et al (2005) Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5:218–227. doi:10.1111/j.1600-6143.2004.00692.x
British Transplantation Society (2004) Guidelines for the prevention and management of cytomegalovirus disease after solid organ transplantation, 2nd edn. British Transplantation Society, London
McCormick PA, Kennedy F (2007) National liver unit liver transplant guidelines. St. Vincent’s University Hospital, Dublin
McDevitt LM (2006) Etiology and impact of cytomegalovirus disease on solid organ transplant recipients. Am J Health Syst Pharm 63(Suppl 5):3–9. doi:10.2146/ajhp060377
Singh N (2006) Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 35:474–477. doi:10.1016/j.jcv.2005.10.014
Limaye AP, Bakthavatsalam R, Kim HW et al (2006) Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81(12):1645–1652. doi:10.1097/01.tp.0000226071.12562.1a
De Gascun CF, Houlihan D, Coughlan S et al (2006) Cytomegalovirus infection in recipients of liver transplant in Ireland (abstract no. P753). Clin Microbiol Infect 12(Suppl 4)
Gane E, Saliba F, Valdecasas GJC et al (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 350:1729–1733. doi:10.1016/S0140-6736(97)05535-9
Paya C, Humar A, Dominguez E et al (2004) Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611–620. doi:10.1111/j.1600-6143.2004.00382.x
Arthurs SK, Eid AJ, Pedersen RA et al (2007) Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 13(12):1703–1709. doi:10.1002/lt.21280
Singh N (2006) Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 16:281–287. doi:10.1002/rmv.513
Author information
Authors and Affiliations
Corresponding author
Additional information
This research was undertaken as part of an MSc in Hospital Pharmacy, awarded by Trinity College Dublin.
Rights and permissions
About this article
Cite this article
Donnelly, C., Kennedy, F., Keane, C. et al. Late-onset CMV disease following CMV prophylaxis. Ir J Med Sci 178, 333–336 (2009). https://doi.org/10.1007/s11845-009-0327-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-009-0327-3